Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Colonic neuronal loss and delayed motility induced by high-fat diet occur independently of changes in the major groups of microbiota in Swiss mice.

Beraldi EJ, Borges SC, de Almeida FLA, Dos Santos A, Saad MJA, Buttow NC.

Neurogastroenterol Motil. 2019 Nov 12:e13745. doi: 10.1111/nmo.13745. [Epub ahead of print]

PMID:
31721393
2.

Resveratrol promotes neuroprotection and attenuates oxidative and nitrosative stress in the small intestine in diabetic rats.

Ferreira PEB, Beraldi EJ, Borges SC, Natali MRM, Buttow NC.

Biomed Pharmacother. 2018 Sep;105:724-733. doi: 10.1016/j.biopha.2018.06.030. Epub 2018 Jun 12.

PMID:
29906751
3.

Toxoplasma gondii promotes changes in VIPergic submucosal neurons, mucosal intraepithelial lymphocytes, and goblet cells during acute infection in the ileum of rats.

Schneider LCL, do Nascimento JCP, Trevizan AR, Góis MB, Borges SC, Beraldi EJ, Garcia JL, Sant'Ana DMG, Buttow NC.

Neurogastroenterol Motil. 2018 May;30(5):e13264. doi: 10.1111/nmo.13264. Epub 2017 Dec 21.

PMID:
29266818
4.

Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).

Borgmann H, Lallous N, Ozistanbullu D, Beraldi E, Paul N, Dalal K, Fazli L, Haferkamp A, Lejeune P, Cherkasov A, Gleave ME.

Eur Urol. 2018 Jan;73(1):4-8. doi: 10.1016/j.eururo.2017.08.012. Epub 2017 Aug 26.

PMID:
28851578
5.

Resveratrol promotes myenteric neuroprotection in the ileum of rats after ischemia-reperfusion injury.

Borges SC, da Silva de Souza AC, Beraldi EJ, Schneider LC, Buttow NC.

Life Sci. 2016 Dec 1;166:54-59. doi: 10.1016/j.lfs.2016.09.016. Epub 2016 Sep 23.

PMID:
27671039
6.

Clusterin knockdown sensitizes prostate cancer cells to taxane by modulating mitosis.

Al Nakouzi N, Wang CK, Beraldi E, Jager W, Ettinger S, Fazli L, Nappi L, Bishop J, Zhang F, Chauchereau A, Loriot Y, Gleave M.

EMBO Mol Med. 2016 Jul 1;8(7):761-78. doi: 10.15252/emmm.201506059. Print 2016 Jul.

7.

siRNA Lipid Nanoparticle Potently Silences Clusterin and Delays Progression When Combined with Androgen Receptor Cotargeting in Enzalutamide-Resistant Prostate Cancer.

Yamamoto Y, Lin PJ, Beraldi E, Zhang F, Kawai Y, Leong J, Katsumi H, Fazli L, Fraser R, Cullis PR, Gleave M.

Clin Cancer Res. 2015 Nov 1;21(21):4845-55. doi: 10.1158/1078-0432.CCR-15-0866. Epub 2015 Jun 23.

8.

A Novel Triazole Nucleoside Suppresses Prostate Cancer Cell Growth by Inhibiting Heat Shock Factor 1 and Androgen Receptor.

Xia Y, Wang M, Beraldi E, Cong M, Zoubeidi A, Gleave M, Peng L.

Anticancer Agents Med Chem. 2015;15(10):1333-40.

PMID:
26081200
9.

Resveratrol Reduces Morphologic Changes in the Myenteric Plexus and Oxidative Stress in the Ileum in Rats with Ischemia/Reperfusion Injury.

da Silva de Souza AC, Borges SC, Beraldi EJ, de Sá-Nakanishi AB, Comar JF, Bracht A, Natali MR, Buttow NC.

Dig Dis Sci. 2015 Nov;60(11):3252-63. doi: 10.1007/s10620-015-3742-5. Epub 2015 Jun 16.

PMID:
26077974
10.

Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer.

Shiota M, Bishop JL, Takeuchi A, Nip KM, Cordonnier T, Beraldi E, Kuruma H, Gleave ME, Zoubeidi A.

Oncotarget. 2015 Apr 20;6(11):9086-98.

11.

Hsp27 Inhibition with OGX-427 Sensitizes Non-Small Cell Lung Cancer Cells to Erlotinib and Chemotherapy.

Lelj-Garolla B, Kumano M, Beraldi E, Nappi L, Rocchi P, Ionescu DN, Fazli L, Zoubeidi A, Gleave ME.

Mol Cancer Ther. 2015 May;14(5):1107-16. doi: 10.1158/1535-7163.MCT-14-0866. Epub 2015 Mar 4.

12.

Generation 2.5 antisense oligonucleotides targeting the androgen receptor and its splice variants suppress enzalutamide-resistant prostate cancer cell growth.

Yamamoto Y, Loriot Y, Beraldi E, Zhang F, Wyatt AW, Al Nakouzi N, Mo F, Zhou T, Kim Y, Monia BP, MacLeod AR, Fazli L, Wang Y, Collins CC, Zoubeidi A, Gleave M.

Clin Cancer Res. 2015 Apr 1;21(7):1675-87. doi: 10.1158/1078-0432.CCR-14-1108. Epub 2015 Jan 29.

13.

Intestinal and neuronal myenteric adaptations in the small intestine induced by a high-fat diet in mice.

Soares A, Beraldi EJ, Ferreira PE, Bazotte RB, Buttow NC.

BMC Gastroenterol. 2015 Jan 22;15:3. doi: 10.1186/s12876-015-0228-z.

14.

Clusterin facilitates stress-induced lipidation of LC3 and autophagosome biogenesis to enhance cancer cell survival.

Zhang F, Kumano M, Beraldi E, Fazli L, Du C, Moore S, Sorensen P, Zoubeidi A, Gleave ME.

Nat Commun. 2014 Dec 12;5:5775. doi: 10.1038/ncomms6775.

15.

Protective effect of metformin against walker 256 tumor growth is not dependent on metabolism improvement.

Franco CC, Miranda RA, de Oliveira JC, Barella LF, Agostinho AR, Prates KV, Malta A, Trombini AB, Torrezan R, Gravena C, Tófolo LP, de Sant'Anna JR, de Castro Prado MA, de Souza CO, de Souza HM, Beraldi EJ, Mathias PC.

Cell Physiol Biochem. 2014;34(6):1920-32. doi: 10.1159/000366390. Epub 2014 Nov 21.

16.

High-fat diet promotes neuronal loss in the myenteric plexus of the large intestine in mice.

Beraldi EJ, Soares A, Borges SC, de Souza AC, Natali MR, Bazotte RB, Buttow NC.

Dig Dis Sci. 2015 Apr;60(4):841-9. doi: 10.1007/s10620-014-3402-1. Epub 2014 Oct 22.

PMID:
25330870
17.

Lyn tyrosine kinase regulates androgen receptor expression and activity in castrate-resistant prostate cancer.

Zardan A, Nip KM, Thaper D, Toren P, Vahid S, Beraldi E, Fazli L, Lamoureux F, Gust KM, Cox ME, Bishop JL, Zoubeidi A.

Oncogenesis. 2014 Aug 18;3:e115. doi: 10.1038/oncsis.2014.30.

18.

Insulin-like growth factor-I induces CLU expression through Twist1 to promote prostate cancer growth.

Takeuchi A, Shiota M, Beraldi E, Thaper D, Takahara K, Ibuki N, Pollak M, Cox ME, Naito S, Gleave ME, Zoubeidi A.

Mol Cell Endocrinol. 2014 Mar 25;384(1-2):117-25. doi: 10.1016/j.mce.2014.01.012. Epub 2014 Feb 1.

PMID:
24491388
19.

Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo.

Thomas C, Lamoureux F, Crafter C, Davies BR, Beraldi E, Fazli L, Kim S, Thaper D, Gleave ME, Zoubeidi A.

Mol Cancer Ther. 2013 Nov;12(11):2342-55. doi: 10.1158/1535-7163.MCT-13-0032. Epub 2013 Aug 21.

20.

Cotargeting Androgen Receptor and Clusterin Delays Castrate-Resistant Prostate Cancer Progression by Inhibiting Adaptive Stress Response and AR Stability.

Matsumoto H, Yamamoto Y, Shiota M, Kuruma H, Beraldi E, Matsuyama H, Zoubeidi A, Gleave M.

Cancer Res. 2013 Aug 15;73(16):5206-17. doi: 10.1158/0008-5472.CAN-13-0359. Epub 2013 Jun 20.

21.

Hsp27 regulates epithelial mesenchymal transition, metastasis, and circulating tumor cells in prostate cancer.

Shiota M, Bishop JL, Nip KM, Zardan A, Takeuchi A, Cordonnier T, Beraldi E, Bazov J, Fazli L, Chi K, Gleave M, Zoubeidi A.

Cancer Res. 2013 May 15;73(10):3109-19. doi: 10.1158/0008-5472.CAN-12-3979. Epub 2013 Mar 14.

22.

Clusterin mediates TGF-β-induced epithelial-mesenchymal transition and metastasis via Twist1 in prostate cancer cells.

Shiota M, Zardan A, Takeuchi A, Kumano M, Beraldi E, Naito S, Zoubeidi A, Gleave ME.

Cancer Res. 2012 Oct 15;72(20):5261-72. doi: 10.1158/0008-5472.CAN-12-0254. Epub 2012 Aug 15.

23.

GRP78 regulates clusterin stability, retrotranslocation and mitochondrial localization under ER stress in prostate cancer.

Li N, Zoubeidi A, Beraldi E, Gleave ME.

Oncogene. 2013 Apr 11;32(15):1933-42. doi: 10.1038/onc.2012.212. Epub 2012 Jun 11.

PMID:
22689054
24.

Cotargeting stress-activated Hsp27 and autophagy as a combinatorial strategy to amplify endoplasmic reticular stress in prostate cancer.

Kumano M, Furukawa J, Shiota M, Zardan A, Zhang F, Beraldi E, Wiedmann RM, Fazli L, Zoubeidi A, Gleave ME.

Mol Cancer Ther. 2012 Aug;11(8):1661-71. doi: 10.1158/1535-7163.MCT-12-0072. Epub 2012 Jun 6.

25.

Hsp27 silencing coordinately inhibits proliferation and promotes Fas-induced apoptosis by regulating the PEA-15 molecular switch.

Hayashi N, Peacock JW, Beraldi E, Zoubeidi A, Gleave ME, Ong CJ.

Cell Death Differ. 2012 Jun;19(6):990-1002. doi: 10.1038/cdd.2011.184. Epub 2011 Dec 16.

26.

Clusterin is a critical downstream mediator of stress-induced YB-1 transactivation in prostate cancer.

Shiota M, Zoubeidi A, Kumano M, Beraldi E, Naito S, Nelson CC, Sorensen PH, Gleave ME.

Mol Cancer Res. 2011 Dec;9(12):1755-66. doi: 10.1158/1541-7786.MCR-11-0379. Epub 2011 Oct 10.

27.

Clusterin inhibition using OGX-011 synergistically enhances Hsp90 inhibitor activity by suppressing the heat shock response in castrate-resistant prostate cancer.

Lamoureux F, Thomas C, Yin MJ, Kuruma H, Beraldi E, Fazli L, Zoubeidi A, Gleave ME.

Cancer Res. 2011 Sep 1;71(17):5838-49. doi: 10.1158/0008-5472.CAN-11-0994. Epub 2011 Jul 7.

28.

Transcription factor Stat5 knockdown enhances androgen receptor degradation and delays castration-resistant prostate cancer progression in vivo.

Thomas C, Zoubeidi A, Kuruma H, Fazli L, Lamoureux F, Beraldi E, Monia BP, MacLeod AR, Thüroff JW, Gleave ME.

Mol Cancer Ther. 2011 Feb;10(2):347-59. doi: 10.1158/1535-7163.MCT-10-0850. Epub 2011 Jan 7.

29.

Hsp27 promotes insulin-like growth factor-I survival signaling in prostate cancer via p90Rsk-dependent phosphorylation and inactivation of BAD.

Zoubeidi A, Zardan A, Wiedmann RM, Locke J, Beraldi E, Fazli L, Gleave ME.

Cancer Res. 2010 Mar 15;70(6):2307-17. doi: 10.1158/0008-5472.CAN-09-3252. Epub 2010 Mar 2. Erratum in: Cancer Res. 2011 Jul 15;71(14):5054.

30.

Clusterin facilitates COMMD1 and I-kappaB degradation to enhance NF-kappaB activity in prostate cancer cells.

Zoubeidi A, Ettinger S, Beraldi E, Hadaschik B, Zardan A, Klomp LW, Nelson CC, Rennie PS, Gleave ME.

Mol Cancer Res. 2010 Jan;8(1):119-30. doi: 10.1158/1541-7786.MCR-09-0277. Epub 2010 Jan 12.

31.

Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity.

Zoubeidi A, Zardan A, Beraldi E, Fazli L, Sowery R, Rennie P, Nelson C, Gleave M.

Cancer Res. 2007 Nov 1;67(21):10455-65.

32.

Hsp27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cells.

Kamada M, So A, Muramaki M, Rocchi P, Beraldi E, Gleave M.

Mol Cancer Ther. 2007 Jan;6(1):299-308. Epub 2007 Jan 11.

33.
34.

Loss of functional E-cadherin renders cells more resistant to the apoptotic agent taxol in vitro.

Ferreira P, Oliveira MJ, Beraldi E, Mateus AR, Nakajima T, Gleave M, Yokota J, Carneiro F, Huntsman D, Seruca R, Suriano G.

Exp Cell Res. 2005 Oct 15;310(1):99-104.

PMID:
16112667
35.

Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer.

Rocchi P, So A, Kojima S, Signaevsky M, Beraldi E, Fazli L, Hurtado-Coll A, Yamanaka K, Gleave M.

Cancer Res. 2004 Sep 15;64(18):6595-602.

36.

Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo.

July LV, Beraldi E, So A, Fazli L, Evans K, English JC, Gleave ME.

Mol Cancer Ther. 2004 Mar;3(3):223-32.

37.
38.
39.
40.

A metastatic and androgen-sensitive human prostate cancer model using intraprostatic inoculation of LNCaP cells in SCID mice.

Sato N, Gleave ME, Bruchovsky N, Rennie PS, Beraldi E, Sullivan LD.

Cancer Res. 1997 Apr 15;57(8):1584-9.

41.

Growth inhibition by anti-estrogens and progestins in TGF-beta-resistant and -sensitive breast-tumor cells.

Kalkhoven E, Beraldi E, Panno ML, De Winter JP, Thijssen JH, Van Der Burg B.

Int J Cancer. 1996 Mar 1;65(5):682-7.

42.

Effects of short-term high-dose testosterone propionate administration on medium molecular-weight proteins of human seminal plasma.

Carpino A, Sisci D, Aquila S, Beraldi E, Sessa MT, Siciliano L, De Luca G, Andò S.

Andrologia. 1994 Jul-Aug;26(4):241-5.

PMID:
7526746
43.

Influence of thyroid hormone on androgen metabolism in peripuberal rat Sertoli cells.

Panno ML, Beraldi E, Pezzi V, Salerno M, De Luca G, Lanzino M, Le Pera M, Sisci D, Prati M, Palmero S, Bolla E, Fugassa E, Andò S.

J Endocrinol. 1994 Mar;140(3):349-55.

PMID:
8182361
44.

Sex steroids levels in the plasma and testis during the reproductive cycle of lizard Podarcis s. sicula Raf.

Andò S, Ciarcia G, Panno ML, Imbrogno E, Tarantino G, Buffone M, Beraldi E, Angelini F, Botte V.

Gen Comp Endocrinol. 1992 Jan;85(1):1-7.

PMID:
1532946
45.

Influence of hypothyroidism on in-vitro testicular steroidogenesis in adult rats.

Andó S, Panno ML, Beraldi E, Tarantino G, Salerno M, Palmero S, Prati M, Fugassa E.

Exp Clin Endocrinol. 1990 Nov;96(2):149-56.

PMID:
2151442
46.

Plasma sex hormone concentrations during the reproductive cycle in the male lizard, Podarcis s. sicula.

Andò S, Panno ML, Ciarcia G, Imbrogno E, Buffone M, Beraldi E, Sisci D, Angelini F, Botte V.

J Reprod Fertil. 1990 Nov;90(2):353-60.

PMID:
2147447
47.

The evaluation of androgen circulating levels following castration in adult male rats.

Andò S, Canonaco M, Beraldi E, Valenti A, Maggiolini M, Piro A, Tavolaro R, Dessì Fulgheri F.

Exp Clin Endocrinol. 1988 Aug;91(3):311-8.

PMID:
2978021
48.

Physiological changes in androgen plasma levels with elapsing of time from castration in adult male rats.

Ando S, Aquila S, Beraldi E, Canonaco M, Panno ML, Valenti A, Dessi-Fulgheri F.

Horm Metab Res. 1988 Feb;20(2):96-9.

PMID:
2967241
50.

Effects of castration on androstenedione, testosterone and dihydrotestosterone plasma levels in adult male rats.

Andò S, Giacchetto C, Canonaco M, Aquila S, Valenti A, Beraldi E, Piro A, Dessì-Fulgheri F.

Horm Res. 1986;23(2):122-7.

PMID:
3943771

Supplemental Content

Loading ...
Support Center